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Abstract
Malaria transmission is in decline in some parts of Africa, partly due to the scaling up of con-
trol measures. If the goal of elimination is to be achieved, additional control measures includ-
ing an effective and durable vaccine will be required. Studies utilising the prime-boost
approach to deliver viral vectors encoding the pre-erythrocytic antigen ME-TRAP (multiple
epitope thrombospondin-related adhesion protein) have shown promising safety, immuno-
genicity and efficacy in sporozoite challenge studies. More recently, a study in Kenyan
adults, similar to that reported here, showed substantial efficacy against P. falciparum infec-
tion. One hundred and twenty healthy male volunteers, living in a malaria endemic area of
Senegal were randomised to receive either the Chimpanzee adenovirus (ChAd63) ME-
TRAP as prime vaccination, followed eight weeks later by modified vaccinia Ankara (MVA)
also encoding ME-TRAP as booster, or two doses of anti-rabies vaccine as a comparator.
Prior to follow-up, antimalarials were administered to clear parasitaemia and then partici-
pants were monitored by PCR for malaria infection for eight weeks. The primary endpoint
was time-to-infection with P. falciparum malaria, determined by two consecutive positive
PCR results. Secondary endpoints included adverse event reporting, measures of cellular
and humoral immunogenicity and a meta-analysis of combined vaccine efficacy with the
parallel study in Kenyan adults.We show that this pre-erythrocytic malaria vaccine is safe
and induces significant immunogenicity, with a peak T-cell response at seven days after
boosting of 932 Spot Forming Cells (SFC)/106 Peripheral Blood Mononuclear Cells(PBMC)
compared to 57 SFC/ 106 PBMCs in the control group. However, a vaccine efficacy was not
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observed: 12 of 57 ME-TRAP vaccinees became PCR positive during the intensive monitor-
ing period as compared to 13 of the 58 controls (P = 0.80). This trial confirms that vaccine
efficacy against malaria infection in adults may be rapidly assessed using this efficient and
cost-effective clinical trial design. Further efficacy evaluation of this vectored candidate vac-
cine approach in other malaria transmission settings and age-de-escalation into the main
target age groups for a malaria vaccine is in progress.
Introduction
Malaria transmission has been on the decline in many parts of Africa in association with scal-
ing up of effective control measures [1–3]. Elimination and subsequent eradication of malaria
has been the subject of discourse for several years [4,5]. However, if the goal of eradication is
to be achieved, additional control measures including effective and durable vaccines will be
required.
The pre-erythocytic malaria vaccine RTS, S targeting the circumsporozoite protein, is the
most advanced vaccine in clinical development. In the recently published Phase III clinical
trial in over 15,000 infants and children in several African countries, the efficacy of RTS, S,
with AS01 as adjuvant, in young children was about 50% during the first year [6–11], but
lower at 34–36% over 4 years [12]. Efficacy declines with time and was much lower against
severe malaria after 3 years of follow-up in younger infants (10–17%)[11]. This partial efficacy
necessitates the development of other candidate vaccines, which could be used alone or in
combination with RTS, S. Studies in multiple disease areas show that vectored vaccines induce
more potent T cell responses that can provide significant efficacy. Heterologous prime-boost
immunisation with chimpanzee adenovirus 63 (ChAd63) and modified vaccinia virus Ankara
(MVA) vectored vaccines is a vaccination strategy recently shown to induce cell-mediated
responses against several P. falciparum malaria antigens [13–15]. ChAd63-MVA expressing
the P. falciparum pre-erythrocytic antigen ME-TRAP (multiple epitope string thrombospon-
din-related adhesion protein) is one of the most advanced malaria vaccine candidates, capable
of inducing sterile protection in 21% of malaria naïve adults following controlled human
malaria infection (CHMI)[16].
Recently in Sukuta, The Gambia and Kilifi, Kenya, two phase Ib dose-escalation clinical tri-
als were undertaken to assess the safety and immunogenicity of this approach in 46 healthy
malaria-exposed adults as previously, immunogenicity had only been described in predomi-
nantly Caucasian, malaria-naïve adults. These two studies showed encouraging results, with
both vaccines shown to be safe and well tolerated, with high-level T cell responses induced
(median > 1300 Spot Forming Cells/million Peripheral Blood Monuclear Cells [14,17]. The T
cell responses appeared to be the most potent reported in Africa for any vaccine type and were
therefore consistent with the growing evidence that ChAd63 and MVA were promising vectors
for clinical use. In Kilifi in Eastern Kenya, malaria is endemic with two transmission seasons
(April-June and October-December) while in Senegal the transmission is made of one short
and intense transmission season (July to August-November). It was therefore useful to assess
the safety, immunogenicity and efficacy of candidate vaccine in semi-immune West African
adults exposed to different malaria transmission conditions.
The use of PCR detection has been found to be feasible and cost-effective in studies con-
ducted in The Gambia and more recently in Kenya [18,19]. These clinical efficacy trials mea-
sure time to PCR-detected infection after drug clearance of parasites. Efficacy against infection
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is measured over an 8-week follow-up period starting 14 days after the final vaccination (7 days
after drug clearance). In a Phase IIb trial of vaccine efficacy in 120 Kenyan adults, efficacy
against infection was 67% (95%CI 33% to 83%), p = 0.002, over 8 weeks of follow-up [19].
Using malaria infection detected by PCR as an endpoint for efficacy, we assessed the safety,
immunogenicity and efficacy of priming with the same vaccines and doses, ChAd63 ME-TRAP
(5 x 105 vp) vaccine and boosting with MVA ME-TRAP (2 x 108 pfu), 8 weeks apart in healthy
adult volunteers in Senegal.
Methods
Registration: Pan African Clinical Trial Registry (Ref: PACTR 201-303-000-499-409); http://
www.pactr.org
Study setting
The study was conducted in the peri-urban area of Dakar in Senegal, West Africa, in one of the
Université Cheikh Anta Diop’s (UCAD) sites located in the Roi Baudoin Hospital in Guédiawaye
from June 2012 to March 2013. Guédiawaye is a small town situated on the coastal shoreline in
the Dakar region, bordered to the East and the South by the town of Pikine and to the West by
the city of Dakar, specifically by the municipal district of Parcelles Assainies [20]. It is located
approximately 10 km from the capital, and covers an area of 30 km2. Its population is estimated
at 452,168 inhabitants and the average annual rainfall amounts to approximately 600 mm. Over
the past few years, malaria transmission has reached record levels in all 5 municipal districts
within the Départment, namely Médina Gounas, Whakhinane Nimzath, Golf Sud, Sam Notaire
and Ndiareme Limamoulaye. There are several reasons that account for the resurgence of
malaria in the Dakar suburbs: (i) a high population density, (ii) cyclic flooding in lowland areas
since the year 2000, (iii) the lack of a drainage system, and (iv) the existence of several wetland
areas (containment basins, marshland, etc.)
Study design and interventions. The study was reviewed and approved by the “Conseil
National d’Ethique pour la Recherche en Santé” (CNERS) of Senegal as well as the “Direction de
la Pharmacie et des Médicaments” (DPM), the Senegalese regulatory authority, and Oxford
Tropical Research Ethics Committee (OXTREC). An independent Data Safety Monitoring
Board (DSMB) provided oversight for the study. An on-site Local Safety Monitor (LSM) acted
as liaison between the site and the DSMB. The study was conducted in accordance with the
Helsinki Declaration of 1964 (revised in 1996) and in accordance with Good Clinical Practice
(Directive 2001/83/EC, amended 2003/63/EC). The University of Oxford acted as study spon-
sor. The trial was registered at the Pan-African Clinical Trial Registry (Ref No: PACTR 201-
303-000-499-409); http://www.pactr.org/ and ClinicalTrials.gov (Ref No: NCT01658696);
http://clinicaltrials.gov.
We conducted a randomised, controlled, single-blinded phase IIb efficacy trial. An inde-
pendent statistician based at the University of Oxford provided sealed randomisation enve-
lopes to the study site. Participants, fieldworker and laboratory analysts were blinded to study
allocation of participants and remained blinded until after analysis was completed. The recom-
binant vectors have been previously described in detail [21]. Eligible study participants were
randomised to receive either the ChAd63 ME-TRAP (5x105 vp) as prime vaccination, followed
eight weeks later by MVA ME-TRAP (2x108 pfu) as booster or two doses of anti-rabies vaccine
(0.5ml) as comparator at the same interval. All vaccines were administered intramuscularly.
Trial participants. Healthy men aged 18–50 years old were screened and 120 eligible vol-
unteers were selected to participate in this trial. Prior to the commencement of the study, local
community sensitisation (collective and individual) meetings were held to introduce to members
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of the community the purpose and nature of the clinical trial. Screening of eligible volunteers
commenced after signed informed consent was obtained. Volunteers enrolled into the study
were required to be in good health, within the age range, and residing in the study area for the
duration of the study. Exclusion of volunteers occurred if there was any physical, haematological
or biochemical evidence of ill health. In order to maintain confidentiality, anonymised HIV test
were conducted using the standard rapid diagnostic kits and testing algorithm used by the Sene-
galese Ministry of Health and Prevention. A trained counsellor provided pre-test counseling. Eli-
gible volunteers who participated in the trial met all of the inclusion criteria and none of the
exclusion criteria.
Assessment of safety and reactogenicity. Volunteers were observed for at least 30 min-
utes after each vaccination. A number of volunteers were assigned to each of the 12 field work-
ers who visited them at home on day one post-vaccination and were assessed in the clinic on
day 14 and 7 after the first and second vaccinations respectively. The local solicited adverse
events (AEs) were; pain, discoloration, swelling, warmth, itch, scaling or blistering at the injec-
tion site. Systemic solicited AEs were; headache, malaise, arthralgia, reported fever, nausea,
myalgia and documented fever (temperature37.5˚C). Using pre-determined criteria, the
intensity of AEs was graded as mild, moderate or severe. Serious adverse events (SAEs) were
recorded during the whole study period. Laboratory abnormalities, recorded as adverse events
were assessed by full blood count, creatinine and alanine aminotransferase.
Drug Treatment prior to PCR monitoring for P. falciparum infection. We adminis-
tered a three-day course of directly observed atovaquone/proguanil (250mg/100mg) and arte-
sunate (250mg) 7 days after the final vaccination (Days 63–65) in order to clear parasitaemia
prior to PCR monitoring for new P. falciparum infections.
Immunogenicity. Immunogenicity to the TRAP antigen was assessed by IgG ELISA and
ex-vivo interferon-gamma (IFNγ) ELISpot. The immunogenicity was determined at D0, D14
(2 weeks post vaccination with ChAd63 ME-TRAP), D63 (7 days post vaccination with MVA-
ME-TRAP) and D161. While ME-TRAP ELISpots were performed on samples from all volun-
teers at D63 (the peak time-point for vaccine-induced cellular immunity), due to the high cost
and staff requirement of the immunology analysis, we did a second randomization to allocate
measurement of ELISpot responses at D0, D14 and D161 to 30 volunteers only. Fresh PBMCs
were isolated from 40 ml of heparinized blood using Lymphoprep (Axis-Shield Diagnostics
Ltd). ELISA and ELISpot assays were performed as previously described [17]. An AID ELI-
SPOT plate reader with software v7 was used to count the spots. The mean of the negative con-
trol wells, containing cells and medium only, was subtracted from the mean of all the other
duplicate wells for each volunteer. The mean response of all ME-TRAP peptide pool wells
were then summed and expressed as SFC per million PBMC. Peptide pools are described in S3
Table. The maximum permitted value of the negative control well was 80 SFC, while the mini-
mum for the positive well was 800 SFC. Responses were deemed positive if they were greater
than the mean plus 3 standard deviations of the negative control wells of all assays performed
in the study, which was 62 SFC.
Neutralising antibodies to the ChAd63 vector were assayed as previously described [17], on
a separately recruited cohort of 205 adults living in the Keur Soce area of Dakar.
Efficacy. Efficacy was assessed by time to detection of malaria parasites in blood by quan-
titative PCR (qPCR) assays. Volunteers were followed up initially for 4 weeks by three times
weekly blood sampling (0.5mls) for qPCR monitoring. Subsequently blood sampling was done
once weekly for a further 4 weeks. Prior to the onset of the qPCR monitoring period, drug
treatment was administered to volunteers to clear parasitaemia. Follow-up began 2 weeks after
the second and final vaccination and 7 days after drug treatment. Volunteers diagnosed with
malaria infection during follow-up were treated according to national guidelines.
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qPCR Monitoring. qPCR monitoring and assays were conducted as previously described
[13,16,18,19,22]. In summary, blood samples were collected on days 0 and 63 for baseline para-
sitaemia and during the efficacy follow-up period, blood was collected three times per week
from day 70 to day 95 and once per week from day 98 to day 119. Blood samples were filtered
with custom Whatman 24 well VFE plates and washed with PBS to remove white cells before
DNA extraction using a modified QIAamp Blood Mini Kit protocol. DNA was extracted from
0.5ml filtered blood and eluted into 50 μl, from which 15 μl (i.e. 5 μl in triplicate) was amplified
by quantitative PCR using primers (forward- 5’ GTAATTGGAATGATAGGAATTTACAA
GGT 3’, reverse- 5’ TCAACTACGAACGTTTTAACTGCAAC 3’) and a TaqMan1 probe (50-
FAM-AACAATTGGAGGGCAAG-NFQ-MGB-30) specific for the multicopy 18S ribosomal
RNA genes. We used an Applied Biosystems 7300 real time PCR system with quantification by
Applied Biosystems 7300 system software v1.4 at UCAD. Similar further analysis of DNA and
repeat QIAamp DNA extractions of frozen filtered blood samples were performed in Oxford
using an Applied Biosystems Step One Plus real time PCR system, analysed using Step One
Plus software v2.3. A pre-planned protocol-specified meta-analysis was conducted that com-
bined the results of the Kenyan and Senegalese studies to give an overall estimate of efficacy
across the two cohorts.
Statistical Analysis. The DSMB, sponsor and investigators agreed an analysis plan before
unblinding. The primary efficacy analysis was the hazard ratio for vaccination as determined
by Cox regression model for first PCR positive blood sample post-vaccination (1972. Regres-
sion models and life tables. J. R. Stat. Soc. 34: 187–220). The secondary efficacy analysis was
the hazard ratio for vaccination, again by Cox regression for first PCR positive blood sample
above a threshold of 10 parasites per ml. The time at risk was considered to begin one week
after the final vaccination with MVA ME-TRAP. All analyses are presented unadjusted and
then adjusted for potential confounders (age and bednet use). Safety data is presented for the
ITT cohort (i.e. including all randomized participants), and immunogenicity and efficacy data
is presented for the ATP cohort (i.e. excluding 3 subjects who did not complete their vaccina-
tion course).
Analysis was done using Stata version 11 (Statacorp, College Station, Texas).
Differences between immunological responses were assessed by Kruskal Wallis tests.
Sample size determination. We expected about 70% of adults to be PCR positive during
follow up, thus providing 90% power to detect an efficacy of 50% and 80% power to detect an
efficacy of 40% with 100 volunteers. The sample size was increased to 120 to allow for loss to
follow up.
Results
Participant baseline characteristics and trial profile
One hundred and seventy one people were screened prior to randomisation and enrollment
of 120 participants. The most common reasons for exclusion were positive hepatitis B
(HBsAg) serology (n = 21), isolated hematology and or biochemistry abnormalities (n = 16)
and abnormalities at the clinical examination (n = 13). One participant travelled to outside
the study area before treatment allocation and was loss to follow up. No positivity to HIV
was found. The participant flow is summarised in Fig 1 and shows an excellent completion
rate in both arms of the study. The study was conducted within the populations living in the
5 districts of Guédiawaye. These five districts were stratified in low, moderate and high
transmission areas. The participants were comparable for age, bednet use and local area of
residence (Table 1).
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Safety
No serious adverse event (SAE) related to vaccination was reported during the study period.
One SAE was observed in the control group. The volunteer reported to the outpatient ward
with fever, headache, chills, articulations pains, asthenia and dizziness and typhoid fever was
Fig 1. Consort 2010 flow diagram
doi:10.1371/journal.pone.0167951.g001
Table 1. Baseline characteristics
TRAP group (n = 60) Control group (n = 60)
Parameter or category Mean/ Freq % or IQR Mean/ Freq % or IQR P
Mean Age (Years) 30.2 28.1 to 32.3 28.4 26.3 to 30.4 0.64
Bed net use 0.18
yes 5 8.3% 10 16.7%
No 55 91.7% 50 83.3%
Location of residence 0.21
Wakhinane Nimzatt & Ndiareme limamoulaye 19 31.7% 18 30%
Sam notaire 12 20.0% 11 18.3%
Medina Gounass 17 28.3% 17 28.3%
Golf Sud 12 20.0% 14 23.3
doi:10.1371/journal.pone.0167951.t001
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diagnosed following examination and investigation. The volunteer was withdrawn from the
study on September 2012.
Pain, itching, redness, swelling and warmth were the most common local adverse events
associated with the administration of the ChAd63 ME-TRAP vaccine Fig 2 with most reported
as mild and some moderate in intensity. Grading criteria were defined in the clinical trial proto-
col and severity assessment criteria are also described in S1 and S2 Tables. The most common
systemic adverse events post-ChAd63 ME-TRAP vaccination were fever, myalgia, discomfort,
headache, arthralgia and nausea mostly mild to moderate with a few severe occurrences. As
previously observed, the MVA ME-TRAP vaccine was more reactogenic than the ChAd63
ME-TRAP vaccine but was still well tolerated with the majority of AEs being mild in intensity.
Similarly, the most common solicited local adverse events reported post-MVA ME- TRAP vac-
cination were swelling, pain, itching and warmth which lasted for between a few hours to 2
days. Systemic AEs reported post-MVA ME-TRAP were arthralgia, fever, headache, myalgia,
nausea and discomfort. All unsolicited adverse events seen within 30 days post-vaccination
were not vaccine related and were mild to moderate in nature.
Clinical malaria cases
With regard to malaria incidence, 5 cases of clinical malaria occurred before the boost vaccina-
tion mostly in the malaria vaccine arm and 6 clinical malaria episodes after the boost vaccina-
tion, 4 of which were in the control group. A very low number of clinical malaria cases were
recorded probably due to the unusually low malaria transmission in the year of the study. In
previous years, higher seasonal transmission had been observed [23].
Fig 2. Local and systemic adverse event profiles for each vaccination, stratified by severity.
doi:10.1371/journal.pone.0167951.g002
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Immunogenicity
Increases in anti-TRAP IgG responses were detected after priming with ChAd63 (log10 geo-
metric mean titre (LGMT) 1.76 CI (1.5–2.0) and boosting with MVA in the ME-TRAP vacci-
nated group (LGMT 2.2, CI 2.0–2.3, p<0.0001 Kruskall-Wallis test, Fig 3A). No increase in
anti-TRAP IgG responses were detected after either vaccination in control group, p = 0.3,
Fig 3. Vaccine immunogenicity. (A and B). Anti-TRAP IgG titres and IFN-γ ELISpot responses to TRAP peptide
pools before and after vaccination. **** p<0.0001, Kruskall-Wallis with Dunn’s post-test; ^^^^ p<0.0001, 2-tailed
Mann Whitney test. Lines represent geometric means. (C). Correlation between humoral and cellular immunogenicity
for ME-TRAP vaccinees, 2-tailed Pearson’s test, n = 54. (D). Proportion of vaccinees with positive responses to TRAP
peptide pools after boosting with MVA. Labels on x-axis refer to peptide pools described in S3 Table. E. Epitope
mapping of TRAP peptide TT1-10, 11–20 and 21–30 using cryopreserved PBMC. Each colour represents a different
volunteer, n = 6. F. Neutralising antibody titres to the ChAd63 vector measured in Senegalese and UK volunteers,
2-tailed Mann-Whitney.
doi:10.1371/journal.pone.0167951.g003
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Kruskall-Wallis test. At the peak of the vaccine-induced humoral response, titres were low, but
comparable in magnitude to those observed in adults from the UK and The Gambia (unpub-
lished data).
The priming vaccination with ChAd63 ME-TRAP induced detectable TRAP-specific T
cells 14 days later as measured by ELISpot, at a geometric mean of 261 SFC per million PBMC
(95% confidence interval (CI) 165–412) compared with 48 SFC (CI 30–79 SFC) among control
vaccinees (p<0.001, Mann Whitney test, Fig 3B). Highest immunogenicity was identified 7
days after boosting vaccination with MVA ME-TRAP, at a geometric mean of 932 SFC (CI
754–1152) compared with 57 SFC per million (95% CI 44–72) among control vaccinees,
p<0.0001 Mann Whitney test). The difference between groups was no longer significant 105
days after MVA ME-TRAP (129 SFC per million PBMC, CI 44–376 compared with 72 spots
per million, 95%CI 33–158, p = 0.3).
There was a positive correlation between humoral and cellular immunogenicity among
ME-TRAP vaccinees (Fig 3C, Pearson’s r = 0.34, p = 0.01). As previously observed with this
antigen, TRAP peptide pools 1, 2, 3 and 6 were most frequently recognized with 66–93% of
TRAP-vaccinated volunteers showing a positive response to these pools at the peak time point
after MVA (Fig 3D). Nineteen percent of vaccinees in the control group had a positive response
to pool 3 and ten percent to pool 1; few responses were detected to other pools. Epitope map-
ping with individual 20mer peptides was performed for pools 1 to 3 in a small number of volun-
teers to identify immunodominant peptides within pools. Responses to at least four peptides in
each pool were detected, although some were to adjacent peptides suggesting epitopes spanned
by two overlapping peptides (Fig 3E).
Neutralising antibodies to the ChAd63 vector, assayed in a separate Senegalese cohort, were
detectable with LGMT of 216 (95% CI 188–247), with 56% of responses above the clinically rele-
vant threshold of 200. In contrast, in a smaller cohort of UK adults [16], responses were higher
(LGMT 370, 95% CI 330–436, p = 0.052, 2-tailed Mann Whitney test, Fig 3F) with 100% of
responses above 200.
Efficacy
Kaplan Meier plots of the distribution of time to PCR positivity are shown in Fig 4. Twelve of
57 ME-TRAP vaccinees became PCR positive during the intensive monitoring period as com-
pared to 13 of the 58 controls. Using Cox regression analysis, efficacy was 8% but was not sta-
tistically significant (95% CI -100% to 59%), p = 0.8; Table 2 and Fig 4A). The secondary
endpoint of PCR positivity (over 10 parasites per ml) also did not show significant protective
efficacy (Fig 4C). There were 11 cases of malaria in the ME-TRAP vaccine arm as compared to
12 in the rabies arm resulting in an unadjusted efficacy of 9% (95% CI -100% to 60%). Efficacy
was not affected by adjustment for covariates (Table 2) and remained non-significant. The
hazard ratios for covariates for the primary endpoint of infection by PCR were long lasting
insecticide-treated bednet use (LLIN) 1.66 (95%CI 0.57–4.8 p = 0.53); and age (per year) 1.01
(95%CI 0.97–1.06 p = 0.5).
Combined analysis of efficacy with analogous study in Kenya
Although the study in Senegal was underpowered to detect vaccine efficacy due to the unex-
pectedly low number of infections during the follow-up period, a protocol-specified meta-
analysis after pooling the data of the Kenyan and Senegalese trials showed significant protec-
tive efficacy of 50% (95% CI 17%-70%; Table 3; Fig 4B and 4D). The difference in transmission
dynamics between the two study sites is demonstrated in Fig 5, showing parasite density for
each volunteer during the study. Volunteers in the Kenyan study that became infected became
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positive only during the first two weeks of PCR monitoring, in contrast to the study in Senegal
where infections were detected throughout the follow-up period. In addition, parasite densities
tended to be much higher in the Senegalese trial.
Discussion
This clinical trial assessed the efficacy of ChAd63-MVA ME-TRAP prime-boost vaccination
against P. falciparum infection in Senegalese adults in Guediawaye a suburb of the capital city
Dakar. The study achieved a good completion rate with 114 volunteers out of 120 completing
the trial and no vaccine-related serious adverse events were observed. The adverse events
reported were mostly mild to moderate, in line with data from previous studies [13,14,21,24]
and overall ChAd63-MVA ME-TRAP was found to be well tolerated.
ELISpot responses to TRAP peptides were detected at all-time points (baseline, day14, day
63 and day 161) in both groups, with baseline responses comparable to those observed in pre-
vious studies in Kenyan, Gambian and UK adults. [17] As expected, T cell immunogenicity in
these malaria-exposed young Senegalese men peaked at one week after the MVA booster dose,
at mean level of 923 SFC per million PBMCs. As previously observed in both malaria-naïve
and semi-immune vaccinees, immunisation with the ME-TRAP construct induced responses
Fig 4. Kaplan-Meier plots of time to first infection. (A) First episode of PCR positivity at any threshold for the trial
in Senegal. (B). Combined analysis of data from the Senegal and Kenya trials. (C). First episode of PCR positivity at
>10 parasites per ml for the trial in Senegal. (D). Combined analysis of data from the Senegal and Kenya trials
doi:10.1371/journal.pone.0167951.g004
Table 2. Vaccine efficacy by Cox regression for any parasitaemia and parasitaemia >10 per ml
TRAP Control Unadjusted Efficacy Adjusted Efficacy
N n N n Efficacy (95% CI) p Efficacy (95% CI) p
Any PCR positivity 57 12 58 13 8% (-200–50%) 0.6 8% (-164–39%) 0.53
>10 parasites/ml 57 11 58 12 9% (-180–50%) 0.8 9% (-141–46%) 0.74
doi:10.1371/journal.pone.0167951.t002
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to several epitopes spanning the length of the antigen, indicating that peptides are recognized
through a number of different MHC alleles. These responses were however lower than those
reported in Kenya at each time point, where the immune response peaked at 1421 SFC [19], as
well as lower than in UK studies where the mean response exceeded 2000 [4].
The surprising difference in immunogenicity found between Kenya and Senegal may par-
tially be explained by several reasons including the lower immunogenicity at baseline in Sene-
gal (60 SFC in Guédiawaye compared with 112 SFC in Kilifi) The ChAd63 ME-TRAP priming
in Kilifi may have acted as a booster dose to naturally acquired immunity. The absence of
malaria exposure in the first weeks of follow up in Senegal may have pushed the rate ratio
towards 1 and obscured any genuine protective efficacy. In other words, with the absence of
malaria risk in both study groups in the first two weeks of the trial, the rate ratio at day 14 was
still 1 and vaccine efficacy (1-RR) = 0. This period of zero vaccine efficacy pulls down the over-
all efficacy for all eight weeks. Malaria transmission is nearly perennial in Kenya with two dif-
ferent transmission seasons, while the transmission pattern in Senegal is very different. There
is a long dry (minimal transmission) season of about 9 months followed by a wet season of
Table 3. Pooled vaccine efficacy by Cox regression for the studies in Kenya and Senegal.
TRAP Control Unadjusted Efficacy*
N n N n Efficacy (95% CI) p
Any PCR positivity 117 23 117 41 50% (17%-70%) 0.009
>10 parasites/ml 117 15 117 31 57% (19%-77%) 0.009
*Analysis of efficacy with adjustment for covariates was not performed as effect of age and bednet use varied between the two sites.
doi:10.1371/journal.pone.0167951.t003
Fig 5. Parasite density as measured by PCR for each trial. Each line represents an individual volunteer.
P = PCR testing performed. During the PCR monitoring follow-up period, blood samples were tested by PCR three
times a week from day 70 to day 95 and once per week from day 98 to day 119.
doi:10.1371/journal.pone.0167951.g005
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3 months. Malaria is actually transmitted only during part of the wet season. Transmission is
therefore intense and short. Outside this transmission window, there may be a total absence of
exposure.
Among 205 adults from another Senegalese population (Keur Socé in Central Senegal),
serum samples tested for anti-ChAd63 neutralizing antibodies indicated that all had previous
exposure to ChAd63 or a related adenovirus. Such results have been observed in other popula-
tions [25] and are most likely due to varying degrees of cross reactivity with related adenovi-
ruses to which volunteers had been exposed. Importantly, this relatively low level of anti-vector
‘s immunity, is found even in European populations (i.e. UK) and have been shown not to asso-
ciate with any reduced immunogenicity of the ChAd63 ME-TRAP vector [17–21], most likely
because the dose of ChAd63 used is sufficient to overcome the modest levels of neutralizing
antibodies to ChAd vectors found in unimmunized humans. A previous malaria efficacy study
evaluating a DNA prime and human adenovirus serotype 5 (AdHu5) vector for boosting did
demonstrate a modest effect of pre-existing anti-vector immunogenicity on ELISA responses to
the AMA1 antigen and trends for association with ELISPOT responses to CSP and AMA1[26].
None of the participants in this study that had high anti-AdHu5 neutralising antibodies prior to
vaccination were protected against CHMI; however there was no statistical association between
anti-vector immunity and efficacy. Therefore, the low prevalence of serum ChAd63-neutraliz-
ing antibodies in Guédiawaye and the excellent immune responses generated even in the pres-
ence of detectable in vitro vector-neutralizing immunity [27–30] make ChAd63 a promising
vaccine vector.
Vaccine efficacy against the primary endpoint (parasitaemia>0) was significantly different
than that observed in the parallel study in Kenya where a vaccine efficacy of 67% was observed. A
pre-specified pooled analysis of the data from both studies using Cox regression showed an over-
all vaccine efficacy in the two populations of 50% (95% confidence interval 17–70%, p = 0.009)
for time to first PCR positivity.
Although the unadjusted confidence intervals of the efficacy estimates in the two sites were
overlapping, there was a significant interaction between the effects of site and vaccination
(p = 0.009) but not with time since vaccination (p = 0.13). This provides statistical evidence
from pooled Senegalese and Kenya datasets that there was variation in efficacy between the
two studies rather than variation in efficacy over time since vaccination.
Several parasitological differences between the two sites that may be relevant to the appar-
ent different vaccine efficacy are noteworthy:
1. PCR positivity was more prevalent before monitoring commenced in Kenya compared to
Senegal;
2. After antimalarial treatment, the incidence of PCR positivity was higher in Kenya yielding
more power to detect efficacy than in the Senegalese study.
3. The PCR data showed higher density parasitaemia in the trial in Senegal compared with the
one in Kilifi, Kenya, representing a potentially more stringent challenge for the vaccine in
the presence of less background malaria immunity. However, this likely reflects lower
malaria transmission in the Senegalese population where the study was done, so that bites
are less frequent and PCR positivity is less frequent; but when an infection occurs because
prior exposure has been lower there is less blood stage immunity and therefore a higher
peak parasitaemia is reached. The PCRs became positive in Kilifi only for a two-week
period after anti-malarial treatment with no positives appearing later. In our Senegal study
in contrast, the emergence of infections was evenly distributed throughout the follow-up
period so that if vaccine efficacy falls very quickly lower efficacy could be seen in Senegal.
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However, the lack of significant interaction between site and time since vaccination in the
combined model (above, p = 0.13) does not support this possibility.
It should be noted that in both sites examples of brief PCR positivity, without sustained par-
asite growth was observed, likely reflecting blood-stage immunity. Microscopy along with the
qPCR was not performed after Atovaquone/Proguanil treatment.
An alternative explanation for the lack of vaccine efficacy in Senegal simply relates to lower
vaccine immunogenicity. In UK CHMI studies a level of> 2000 SFU / million PBMCs was
induced consistently by the ChAd-MVA regime [15–21] and this was associated with significant
efficacy that correlated with T cell numbers. Notably the ChAd63 vaccine alone induced about
864 SFU / million PBMCs and no sterile protection or delay to patency was observed. The Ken-
yan response level was a geometric mean of 1694 SFU, closer to the UK ChAd63-MVA level.
Hence, the reduction in T cell immunogenicity in Senegal to levels close to that seen with the
non-protective ChAd63 only vaccination in the UK might in part explain lower efficacy. If so,
this would highlight the need to use vaccine regimes and doses that consistently induce high-
level T cell responses in every population.
In addition to enhancing cellular immune responses to TRAP, vaccine efficacy might
potentially be improved by including additional liver-stage antigens, such as PfLSA1 and
PfLSAP2. These antigens have recently been shown to induce sterile efficacy against transgenic
parasites in a murine model of malaria and are progressing to clinical evaluation [31]. Another
promising strategy is a combination approach harnessing the ability of viral vectors to induce
potent cellular immunity in combination with a protein-in-adjuvant approach to inducing
high antibody titres. We have recently reported high efficacy of such an approach combining
the leading malaria vaccine candidate RTS,S with ChAd63 and MVA ME-TRAP [32].
Overall, the results of safety, immunogenicity and efficacy of the ChAd63-MVA vaccination
strategy in Kenyan and Senegalese young men gave encouraging results and provide, to our
knowledge, the first indication of potential field efficacy of any vaccine designed to induce pro-
tective cellular immunity. It is now important that protective efficacy be assessed in younger
populations, especially young children and infants, and these trials are underway.
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